PE20121467A1 - Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica - Google Patents
Formulacion de aerosol para la enfermedad pulmonar obstructiva cronicaInfo
- Publication number
- PE20121467A1 PE20121467A1 PE2012000851A PE2012000851A PE20121467A1 PE 20121467 A1 PE20121467 A1 PE 20121467A1 PE 2012000851 A PE2012000851 A PE 2012000851A PE 2012000851 A PE2012000851 A PE 2012000851A PE 20121467 A1 PE20121467 A1 PE 20121467A1
- Authority
- PE
- Peru
- Prior art keywords
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- aerosol formulation
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229960000193 formoterol fumarate Drugs 0.000 abstract 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
- B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
- B65B31/10—Adding propellants in solid form to aerosol containers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE SOLUCIONES EN AEROSOL QUE COMPRENDE: A) BROMURO DE GLICOPIRRONIO DISUELTO EN UN PROPULSOR DE HIDROFLUOROALCANO EN UNA CANTIDAD DE 0.005% A 0.14% P/P DE LA COMPOSICION; B) UN COSOLVENTE TAL COMO ETANOL; C) ACIDO CLORHIDRICO 1M EN UNA CANTIDAD DE 0.005 ug/ul A 1.0 ug/ul; D) UNO O MAS PRINCIPIOS ACTIVOS TALES COMO FUMARATO DE FORMOTEROL, DIPROPIONATO DE BECLOMETASONA, ENTRE OTROS. DICHA COMPOSICION MEJORA LA ESTABILIDAD DEL BROMURO DE GLICOPIRRONIO SIENDO UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09015980 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121467A1 true PE20121467A1 (es) | 2012-11-07 |
Family
ID=42046446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000851A PE20121467A1 (es) | 2009-12-23 | 2010-12-22 | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US20110150783A1 (es) |
| EP (1) | EP2515854B1 (es) |
| JP (1) | JP5800829B2 (es) |
| KR (1) | KR101747474B1 (es) |
| CN (1) | CN102665680B (es) |
| AU (2) | AU2010334858A1 (es) |
| CA (1) | CA2785317C (es) |
| CL (1) | CL2012001668A1 (es) |
| CO (1) | CO6551734A2 (es) |
| CY (1) | CY1115109T1 (es) |
| DK (1) | DK2515854T3 (es) |
| EA (1) | EA021604B1 (es) |
| ES (1) | ES2464520T3 (es) |
| GE (1) | GEP20166479B (es) |
| HR (1) | HRP20140550T1 (es) |
| IL (1) | IL220534A0 (es) |
| MA (1) | MA33821B1 (es) |
| MX (1) | MX340264B (es) |
| MY (1) | MY156950A (es) |
| NZ (1) | NZ600789A (es) |
| PE (1) | PE20121467A1 (es) |
| PH (1) | PH12012501063A1 (es) |
| PL (1) | PL2515854T3 (es) |
| PT (1) | PT2515854E (es) |
| RS (1) | RS53355B (es) |
| SG (1) | SG181870A1 (es) |
| SI (1) | SI2515854T1 (es) |
| TN (1) | TN2012000261A1 (es) |
| UA (1) | UA106098C2 (es) |
| WO (1) | WO2011076842A2 (es) |
| ZA (1) | ZA201204613B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53355B (sr) * | 2009-12-23 | 2014-10-31 | Chiesi Farmaceutici S.P.A. | Aerosolna formulacija za copd (hronične obstruktivne pulmonarne bolesti) |
| CN102665678B (zh) * | 2009-12-23 | 2014-07-02 | 奇斯药制品公司 | 用于copd的联合治疗 |
| PE20121396A1 (es) | 2009-12-23 | 2012-10-24 | Chiesi Farma Spa | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol |
| SI3089735T1 (sl) * | 2013-12-30 | 2018-10-30 | Chiesi Farmaceutici S.P.A. | Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol |
| PL3096737T3 (pl) * | 2013-12-30 | 2018-08-31 | Chiesi Farmaceutici S.P.A. | Stabilna kompozycja w postaci ciśnieniowego roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
| US11559505B2 (en) | 2015-12-04 | 2023-01-24 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CA3037092C (en) * | 2016-09-19 | 2022-06-21 | Mexichem Fluor S.A. De C.V. | Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis) |
| WO2020084549A1 (en) * | 2018-10-25 | 2020-04-30 | Glenmark Specialty S.A. | Nebulization composition comprising glycopyrrolate and formoterol |
| AU2021314977B2 (en) | 2020-07-31 | 2025-03-13 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| CN112051346A (zh) * | 2020-09-24 | 2020-12-08 | 珠海瑞思普利生物制药有限公司 | 一种同时测定茚达特罗和格隆溴铵含量的hplc方法 |
| PE20240629A1 (es) | 2020-10-09 | 2024-03-26 | Chiesi Farm Spa | Formulacion farmaceutica para inhalador presurizado de dosis medidas |
| JP2025517809A (ja) | 2022-05-27 | 2025-06-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量噴霧吸入器のための医薬製剤 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| RO117414B1 (ro) | 1992-12-09 | 2002-03-29 | Jager Paul D Waterbury | Compozitie farmaceutica de aerosol in solutie |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| HU230804B1 (hu) * | 2000-05-22 | 2018-06-28 | Chiesi Farmaceutici S.P.A | Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| DK1372608T3 (da) * | 2001-03-30 | 2007-12-27 | Jagotec Ag | Medicinske aerosolformuleringer |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| HUE049426T2 (hu) | 2002-03-01 | 2020-09-28 | Chiesi Farm Spa | Szuperfinom formoterolkészítmény |
| KR20050085650A (ko) | 2002-12-16 | 2005-08-29 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 타이오트로피움 함유 ｈｆｃ 용액 제형 |
| NZ548302A (en) | 2004-02-06 | 2010-04-30 | Meda Pharma Gmbh & Co Kg | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP2200550B1 (en) | 2007-10-18 | 2018-04-18 | Rose U, LLC | Topical glycopyrrolate formulations |
| EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
| ES2467928T3 (es) * | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| PE20121396A1 (es) * | 2009-12-23 | 2012-10-24 | Chiesi Farma Spa | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol |
| CN102665678B (zh) | 2009-12-23 | 2014-07-02 | 奇斯药制品公司 | 用于copd的联合治疗 |
| RS53355B (sr) * | 2009-12-23 | 2014-10-31 | Chiesi Farmaceutici S.P.A. | Aerosolna formulacija za copd (hronične obstruktivne pulmonarne bolesti) |
| ES2628891T3 (es) * | 2010-08-03 | 2017-08-04 | Chiesi Farmaceutici S.P.A. | Formulación farmacéutica que comprende un inhibidor de fosfodiesterasa |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| PL3096737T3 (pl) | 2013-12-30 | 2018-08-31 | Chiesi Farmaceutici S.P.A. | Stabilna kompozycja w postaci ciśnieniowego roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
| SI3089735T1 (sl) * | 2013-12-30 | 2018-10-30 | Chiesi Farmaceutici S.P.A. | Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol |
-
2010
- 2010-12-22 RS RS20140289A patent/RS53355B/sr unknown
- 2010-12-22 AU AU2010334858A patent/AU2010334858A1/en not_active Abandoned
- 2010-12-22 HR HRP20140550AT patent/HRP20140550T1/hr unknown
- 2010-12-22 KR KR1020127014530A patent/KR101747474B1/ko active Active
- 2010-12-22 CN CN201080058049.2A patent/CN102665680B/zh active Active
- 2010-12-22 MX MX2012006879A patent/MX340264B/es active IP Right Grant
- 2010-12-22 EA EA201290374A patent/EA021604B1/ru active Protection Beyond IP Right Term
- 2010-12-22 CA CA2785317A patent/CA2785317C/en active Active
- 2010-12-22 SI SI201030640T patent/SI2515854T1/sl unknown
- 2010-12-22 PT PT107990293T patent/PT2515854E/pt unknown
- 2010-12-22 DK DK10799029.3T patent/DK2515854T3/da active
- 2010-12-22 PE PE2012000851A patent/PE20121467A1/es active IP Right Grant
- 2010-12-22 MY MYPI2012002845A patent/MY156950A/en unknown
- 2010-12-22 PH PH1/2012/501063A patent/PH12012501063A1/en unknown
- 2010-12-22 EP EP10799029.3A patent/EP2515854B1/en active Active
- 2010-12-22 NZ NZ600789A patent/NZ600789A/en unknown
- 2010-12-22 GE GEAP201012755A patent/GEP20166479B/en unknown
- 2010-12-22 ES ES10799029.3T patent/ES2464520T3/es active Active
- 2010-12-22 SG SG2012046173A patent/SG181870A1/en unknown
- 2010-12-22 WO PCT/EP2010/070478 patent/WO2011076842A2/en not_active Ceased
- 2010-12-22 UA UAA201207627A patent/UA106098C2/uk unknown
- 2010-12-22 JP JP2012545322A patent/JP5800829B2/ja active Active
- 2010-12-22 PL PL10799029T patent/PL2515854T3/pl unknown
- 2010-12-23 US US12/977,181 patent/US20110150783A1/en not_active Abandoned
-
2012
- 2012-05-25 TN TNP2012000261A patent/TN2012000261A1/en unknown
- 2012-06-14 MA MA34964A patent/MA33821B1/fr unknown
- 2012-06-19 CL CL2012001668A patent/CL2012001668A1/es unknown
- 2012-06-21 IL IL220534A patent/IL220534A0/en active IP Right Grant
- 2012-06-21 CO CO12104134A patent/CO6551734A2/es not_active Application Discontinuation
- 2012-06-21 ZA ZA2012/04613A patent/ZA201204613B/en unknown
-
2014
- 2014-05-26 CY CY20141100374T patent/CY1115109T1/el unknown
-
2015
- 2015-07-06 US US14/791,553 patent/US10806701B2/en active Active
-
2016
- 2016-09-27 AU AU2016234894A patent/AU2016234894B2/en active Active
-
2020
- 2020-09-14 US US17/019,740 patent/US11590074B2/en active Active
-
2023
- 2023-01-11 US US18/153,096 patent/US12357568B2/en active Active
-
2025
- 2025-05-09 US US19/203,758 patent/US20250262151A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121467A1 (es) | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica | |
| PE20091691A1 (es) | Formulacion para inhalacion que comprende aclidinio | |
| PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
| CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
| PE20141048A1 (es) | Combinacion que comprende umeclidinio y un corticosteroide | |
| IN2012DN03130A (es) | ||
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| WO2011141929A3 (en) | Aqueous pharmaceutical compositions of fluticasone and olopatadine | |
| PE20120023A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| IN2014CN02591A (es) | ||
| PE20070977A1 (es) | Formulacion farmaceutica que comprende pleconaril | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| CL2013002542A1 (es) | Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. | |
| CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
| UY31687A1 (es) | Nueva dosificacion y formulacion | |
| PE20150171A1 (es) | Nueva forma de dosificacion y formulacion de abediterol | |
| CL2011002302A1 (es) | Uso de una composicion que comprende un monocaprina y un diluyente farmaceuticamente aceptable para el tratamiento de una condicion micotica causada por trichophyton rubrum tal como tinea pedis, tinea crusis, dermatofitosis y onicomicosis. | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| WO2011089126A3 (en) | Novel retigabine composition | |
| CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| MX2018014752A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
| BR112012021445A2 (pt) | formulação farmacêutica ou neutracêutica. | |
| WO2011143271A3 (en) | Therapeutic liposomes and methods for producing and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration |